Olaparib published presentations and documents on DocSlides.
Opinion. 55 year-old woman with . recurrent . ova...
9/8/2016 . Erica . Takimoto. , D.O., F.A.C.O.O.G....
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
This program will include a discussion of off-lab...
BRCA. -Mutated Advanced Ovarian Cancer. Moderator...
PARP Inhibitors: What Do We know?. PARP Inhibitor...
Phase I Study of Olaparib and Temozolomide, in pa...
Phase I Study of Olaparib and Temozolomide, in pa...
highlights from the. EUROPEAN . society . of med...
Inhibitors:. Purpose and Practicalities . Present...
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
proceedings from the live CME event and may includ...
actual. . video-recorded proceedings from the . l...
Five-year . survival. 15%. 30%. 40%. ?50%?. First ...
Laura Yarram-Smith . Solid Tumour Lead SWGLH. J...
Latest developments. . Prof.. . Neeraj Agarwal, ...
Emmanuel . S . Antonarakis. , MD. Professor of Onc...
Understanding the Factors Affecting the Optimal Di...
knowledge. ). Incorporate evidence-based research ...
Copyright © 2024 DocSlides. All Rights Reserved